Real-World Outcomes of Adalimumab Treatment for Moderate and Severe Psoriasis in Korean Patients (RAPSODI Study)

Overview

Journal Ann Dermatol

Specialty Dermatology

Date 2023 Apr 12

PMID 37041704

Authors

Dong Hyun Kim

Sang Wook Son

Ki-Heon Jeong

Jiyoung Ahn

Eun-So Lee

Il-Hwan Kim

Un Ha Lee

Hai-Jin Park

Joo Yeon Ko

Byung-Soo Kim

Jin Ju Kim

Javed Rashid

Kwang Joong Kim

Affiliations

Soon will be listed here.

Abstract

Background: Psoriasis imposes a significant treatment burden on patients, particularly impacting well-being and quality of life (QoL). The psychosocial impact of psoriasis treatments remains unexplored in most patient populations.

Objective: To assess the impact of adalimumab on health-related QoL (HRQoL) in Korean patients with psoriasis.

Methods: This 24-week, multicenter, observational study, assessed HRQoL in Korean patients treated with adalimumab in a real-world setting. Patient-reported outcomes (PROs) including European Quality of Life-5 Dimension scale (EQ-5D), EQ-5D VAS, SF-36, and DLQI were evaluated at week 16 and 24, versus baseline. Patient satisfaction was assessed using TSQM.

Results: Among 97 enrolled patients, 77 were assessed for treatment effectiveness. Most patients were male (52, 67.5%) and mean age was 45.4 years. Median baseline body surface area and Psoriasis Area and Severity Index (PASI) scores were 15.00 (range 4.00~80.00) and 12.40 (range 2.70~39.40), respectively. Statistically significant improvements in all PROs were observed between baseline and week 24. Mean EQ-5D score improved from 0.88 (standard deviation [SD], 0.14) at baseline to 0.91 (SD, 0.17) at week 24 (=0.0067). The number of patients with changes in PASI 75, 90, or 100 from baseline to week 16 and 24 were 65 (84.4%), 17 (22.1%), and 1 (1.3%); and 64 (83.1%), 21 (27.3%), and 2 (2.6%), respectively. Overall treatment satisfaction was reported, including effectiveness and convenience. No unexpected safety findings were noted.

Conclusion: Adalimumab improved QoL and was well-tolerated in Korean patients with moderate to severe psoriasis, as demonstrated in a real-world setting. Clinical trial registration number (clinicaltrials.gov: NCT03099083).

References

de Arruda L, de Moraes A . The impact of psoriasis on quality of life. Br J Dermatol. 2001; 144 Suppl 58:33-6. DOI: 10.1046/j.1365-2133.2001.144s58033.x. View

Reich K, Segaert S, van de Kerkhof P, Durian C, Boussuge M, Paolozzi L . Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis. Dermatology. 2009; 219(3):239-49. DOI: 10.1159/000237871. View

Lee J, Kang S, Park J, Jo S . Prevalence of Psoriasis in Korea: A Population-Based Epidemiological Study Using the Korean National Health Insurance Database. Ann Dermatol. 2017; 29(6):761-767. PMC: 5705359. DOI: 10.5021/ad.2017.29.6.761. View

Leman J, Walton S, Layton A, Ward K, McBride S, Cliff S . The real world impact of adalimumab on quality of life and the physical and psychological effects of moderate-to-severe psoriasis: a UK prospective, multicenter, observational study. J Dermatolog Treat. 2019; 31(3):213-221. DOI: 10.1080/09546634.2019.1592096. View

Gupta M, Gupta A . Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and management. Am J Clin Dermatol. 2003; 4(12):833-42. DOI: 10.2165/00128071-200304120-00003. View

Wolf P, Weger W, Legat F, Painsi C, Saxinger W, Mullegger R . Quality of life and treatment goals in psoriasis from the patient perspective: results of an Austrian cross-sectional survey. J Dtsch Dermatol Ges. 2018; 16(8):981-990. DOI: 10.1111/ddg.13613. View

Anstey A, McAteer H, Kamath N, Percival F . Extending psychosocial assessment of patients with psoriasis in the UK, using a self-rateds, web-based survey. Clin Exp Dermatol. 2012; 37(7):735-40. DOI: 10.1111/j.1365-2230.2012.04457.x. View

Revicki D, Willian M, Menter A, Gordon K, Kimball A, Leonardi C . Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat. 2007; 18(6):341-50. DOI: 10.1080/09546630701646172. View

Strober B, Ryan C, van de Kerkhof P, van der Walt J, Kimball A, Barker J . Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2019; 82(1):117-122. DOI: 10.1016/j.jaad.2019.08.026. View

10.

Bhosle M, Kulkarni A, Feldman S, Balkrishnan R . Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006; 4:35. PMC: 1501000. DOI: 10.1186/1477-7525-4-35. View

11.

Croom K, McCormack P . Adalimumab: in plaque psoriasis. Am J Clin Dermatol. 2009; 10(1):43-50. DOI: 10.2165/0128071-200910010-00008. View

12.

Connor C, Liu V, Fiedorowicz J . Exploring the Physiological Link between Psoriasis and Mood Disorders. Dermatol Res Pract. 2015; 2015:409637. PMC: 4624926. DOI: 10.1155/2015/409637. View

13.

Kim W, Jerome D, Yeung J . Diagnosis and management of psoriasis. Can Fam Physician. 2017; 63(4):278-285. PMC: 5389757. View

14.

Peng C, Xu X, Chen W, Li X, Yi X, Ding Y . Epidemiological Variations in the Global Burden of Psoriasis, an Analysis With Trends From 1990 to 2017. Front Med (Lausanne). 2021; 8:585634. PMC: 7884455. DOI: 10.3389/fmed.2021.585634. View

15.

Fortune D, Richards H, Kirby B, McElhone K, Main C, Griffiths C . Successful treatment of psoriasis improves psoriasis-specific but not more general aspects of patients' well-being. Br J Dermatol. 2004; 151(6):1219-26. DOI: 10.1111/j.1365-2133.2004.06222.x. View

16.

Burgos-Pol R, Martinez-Sesmero J, Ventura-Cerda J, Elias I, Caloto M, Casado M . The Cost of Psoriasis and Psoriatic Arthritis in 5 European Countries: A Systematic Review. Actas Dermosifiliogr. 2016; 107(7):577-90. DOI: 10.1016/j.ad.2016.04.018. View

17.

Kurd S, Troxel A, Crits-Christoph P, Gelfand J . The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010; 146(8):891-5. PMC: 2928071. DOI: 10.1001/archdermatol.2010.186. View

18.

Patel N, Nadkarni A, Cardwell L, Vera N, Frey C, Patel N . Psoriasis, Depression, and Inflammatory Overlap: A Review. Am J Clin Dermatol. 2017; 18(5):613-620. DOI: 10.1007/s40257-017-0279-8. View

19.

AlQassimi S, Albrashdi S, Galadari H, Hashim M . Global burden of psoriasis - comparison of regional and global epidemiology, 1990 to 2017. Int J Dermatol. 2020; 59(5):566-571. DOI: 10.1111/ijd.14864. View

20.

Revicki D, Willian M, Saurat J, Papp K, Ortonne J, Sexton C . Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2007; 158(3):549-57. DOI: 10.1111/j.1365-2133.2007.08236.x. View